Hashimoto's Disease: The Most Common Cause of Hypothyroidism

Hashimoto's thyroiditis, first described by Japanese physician Hakaru Hashimoto in 1912, is the most prevalent autoimmune disorder in the world and the leading cause of hypothyroidism in countries with adequate iodine intake. The condition affects an estimated 14 million people in the United States alone, with women diagnosed roughly seven times more often than men.

What Happens in Hashimoto's

In Hashimoto's thyroiditis, the immune system mistakenly identifies thyroid tissue as foreign and mounts a chronic inflammatory attack against it. Immune cells — primarily lymphocytes — infiltrate the thyroid gland and gradually destroy the cells that produce thyroid hormone. Over months to years, this destruction reduces the gland's capacity to meet the body's hormone needs.

The process is not sudden. Many people carry thyroid antibodies for years before their thyroid function becomes measurably impaired. The condition often progresses through stages: first, antibodies appear with normal thyroid function; then subclinical hypothyroidism develops (elevated TSH, normal free T4); and eventually, overt hypothyroidism emerges with clearly abnormal hormone levels and symptoms.

Occasionally, early in the disease, the destruction of thyroid cells releases stored hormone into the bloodstream, causing a transient phase of hyperthyroidism known as Hashitoxicosis. This typically lasts a few weeks before the expected hypothyroid pattern takes over.

Who Gets Hashimoto's

The strongest risk factor is sex — the overwhelming majority of cases occur in women. The condition most commonly appears between ages 30 and 50, though it can develop at any age, including childhood.

Genetics play a significant role. Having a first-degree relative with Hashimoto's or another autoimmune condition substantially increases risk. Specific genes in the HLA (human leukocyte antigen) complex have been linked to susceptibility, though no single gene determines whether someone will develop the disease.

Environmental factors also contribute:

• Excess iodine intake may accelerate thyroid autoimmunity in genetically predisposed individuals. This is one reason hypothyroidism rates increased in some countries after iodine fortification programs.
• Selenium deficiency has been associated with higher rates of thyroid autoimmunity in epidemiological studies, though the clinical significance of selenium supplementation remains debated.
• Viral infections, particularly hepatitis C, have been linked to higher rates of thyroid antibodies.
• Pregnancy can trigger or unmask Hashimoto's — the immune shifts that occur during and after pregnancy may precipitate autoimmune thyroid disease in susceptible women.
• Smoking has a complex relationship with thyroid autoimmunity. It appears to slightly reduce the risk of hypothyroidism but worsens outcomes in those who develop thyroid eye disease.

Symptoms

Hashimoto's symptoms are essentially the symptoms of the hypothyroidism it causes. Early in the disease, when thyroid function is still normal, there may be no symptoms at all — only positive antibody tests on blood work.

As hypothyroidism develops, the familiar constellation of symptoms appears: fatigue, weight gain, cold intolerance, dry skin, constipation, depression, and cognitive slowing. Some patients also notice a painless enlargement of the thyroid (goiter), which occurs as the gland swells with inflammatory cells. In some cases, the thyroid eventually atrophies and shrinks rather than enlarging.

Diagnosis

Diagnosis typically involves two findings: evidence of hypothyroidism on thyroid function tests (elevated TSH, low or low-normal free T4) and positive thyroid antibodies. TPO (thyroid peroxidase) antibodies are the most commonly tested and are found in about 95% of Hashimoto's patients. Thyroglobulin antibodies may also be elevated.

An ultrasound may show a characteristic pattern of diffuse heterogeneity and reduced echogenicity, sometimes described as a "moth-eaten" appearance. However, ultrasound is not required for diagnosis when antibodies and thyroid function tests are consistent with Hashimoto's.

It is worth noting that about 5% of the general population has positive TPO antibodies without clinical thyroid disease. A positive antibody test alone, without any abnormality in TSH or free T4, does not necessarily mean treatment is needed — but it does warrant periodic monitoring because the risk of progressing to hypothyroidism is roughly 2-5% per year.

Treatment

Treatment for Hashimoto's is treatment for the hypothyroidism it causes. There is currently no approved therapy that stops or reverses the autoimmune process itself.

Levothyroxine replacement is the standard of care and is the same treatment used for hypothyroidism from any cause. The dose is adjusted based on TSH levels, with the goal of normalizing thyroid function and relieving symptoms. Most patients respond well and feel significantly better once the correct dose is established.

For patients who remain symptomatic despite normal TSH levels, some endocrinologists will trial a narrower TSH target (for instance, aiming for TSH in the lower half of the normal range rather than simply anywhere within it). Whether this helps is debated, and evidence for a consistent benefit is limited.

Patients with positive antibodies but normal thyroid function (euthyroid Hashimoto's) generally do not require treatment. They should have TSH checked annually, or sooner if symptoms develop.

Associated Conditions

Hashimoto's does not exist in isolation. Having one autoimmune condition increases the likelihood of developing others. Conditions that occur at higher rates in people with Hashimoto's include:

• Type 1 diabetes
• Celiac disease
• Rheumatoid arthritis
• Vitiligo
• Pernicious anemia (vitamin B12 deficiency due to autoimmune gastritis)
• Addison's disease (adrenal insufficiency)
• Sjogren's syndrome

Some guidelines recommend screening Hashimoto's patients for celiac disease, particularly if gastrointestinal symptoms are present, and checking vitamin B12 levels if there are signs of anemia or neurological symptoms.

There is also a small but established association between Hashimoto's and thyroid lymphoma, a rare cancer. A suddenly enlarging goiter in a patient with longstanding Hashimoto's should be evaluated promptly, though the overall risk remains very low.

Living with Hashimoto's

For the majority of patients, Hashimoto's is a manageable condition. The medication is inexpensive and well-tolerated. The main requirement is consistency: taking levothyroxine daily and getting periodic blood tests to ensure the dose remains appropriate.

There is considerable interest in dietary and lifestyle approaches to managing Hashimoto's. Some patients report improvement with gluten-free diets, particularly those who have concurrent celiac disease or gluten sensitivity. A few small studies have suggested that selenium supplementation may reduce TPO antibody levels, though whether this translates into clinical benefit is unclear. The ATA does not currently recommend selenium supplementation as standard treatment.

Stress management, regular exercise, and adequate sleep are broadly beneficial and may help with fatigue and mood symptoms. These are not substitutes for medication when thyroid hormone levels are low, but they complement medical treatment and contribute to overall quality of life.